Tissue-engineered cardiac patches enriched with IGF1 modified mRNA alleviate myocardial infarction by enhancing cell survival and angiogenesis
Year: 2025
Type: article
Abstract: Tissue-engineered cardiac patches (TECPs), which combine cells with biomaterial scaffolds, hold great promise for myocardial repair and regeneration. However, their broader application remains limited by the low survival rate of transplanted cells. To boost the therapeutic efficacy of cardiac patches, genetic engineering and localized delivery of bioactive factors are essential for optimizing cellular function in vivo. In this study, nanofibrous membranes composed of polycaprolactone-co-l-lactide (PLCL) and gelatin at various ratios were fabricated using electrospinning technology. Among these, membranes containing 30 % gelatin displayed optimal properties, promoting the adhesion, survival, proliferation, and cardiomyocyte differentiation of induced pluripotent stem cell-derived cardiac progenitor cells (iPSC-CPCs). Following this, TECPs were constructed in vitro and transfected with modified mRNA (modRNA) encoding insulin-like growth factor 1 (IGF1). Further evaluations revealed that IGF1 modified mRNA (modIGF1)-enriched TECPs significantly reduced infarct size, enhanced the survival and proliferation of transplanted cells, promoted vascularization and facilitated cardiac functional recovery. The integration of modRNA technology with myocardial patches facilitates the controlled release of therapeutic proteins, thereby preserving cellular function and offering a promising approach to advancing cardiac tissue engineering.
Source: Materials Today Bio
Authors: Bingqian Yan, Xuefeng Ai, Huijing Wang, Yao Tan, Yiqi Gong, Li Yang, Ying Chen, Tingting Lu, Minglu Liu, Runjiao Luo, Kaixiang Li, Xin Tang, Wei Wang, Wei Fu
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,400
Awards: G1083782288, G9000228904
OpenAlex ID: W7116054677